Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma

5T4 (trophoblast glycoprotein, TPBG) is a transmembrane tumor antigen expressed on more than 90% of primary renal cell carcinomas (RCC) and a wide range of human carcinomas but not on most somatic adult tissues. The favorable expression pattern has encouraged the development and clinical testing of...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yuexin, Morales, Alicia J., Cargill, Michael J., Towlerton, Andrea M. H., Coffey, David G., Warren, Edus H., Tykodi, Scott S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877496/
https://www.ncbi.nlm.nih.gov/pubmed/31686124
http://dx.doi.org/10.1007/s00262-019-02419-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877496/
https://www.ncbi.nlm.nih.gov/pubmed/31686124
http://dx.doi.org/10.1007/s00262-019-02419-4

Ejemplares similares